The First International Symposium on Pheochromocytoma, held in October 2005, included discussions about developments concerning these rare catecholamine-producing tumors. Recommendations were made ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

pheochromocytoma, paraganglioma (glomus jugulare tumor), pancreatic neuroendocrine tumor, endometrial cancer, rhabdomyosarcoma, non-rhabdomyosarcoma, Wilms' tumor (nephroblastoma), Ewing sarcoma, ...

Sweaty feet can be caused by several factors, from lifestyle and shoewear to medical conditions. Here are the potential ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma and ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application for expanded use of the oral cancer drug Welireg.

The National Medical Commission (NMC) has issued Guidelines for the competency-based postgraduate training programme for MCh ...

and pheochromocytoma In the absence of data on specific therapies, management of orthostatic hypertension should be a function mainly of the condition of which it is a feature, and might include ...